Cypherpunk Swings To Q2 Profit On Zcash Treasury Gains; Advances Phase 3 Sirexatamab Plans;Stock Up
Cypherpunk Technologies (CYPH) reported a Q2 profit of $39.4M, driven by a $46M gain on Zcash (ZEC) holdings. The company holds 323,394.38 ZEC, valued at $129.4M. Leap Therapeutics, a subsidiary, is advancing sirexatamab for mCRC with FDA alignment on a Phase 3 trial. CYPH stock rose 35.12% to $2.27.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on profitability and crypto exposure, influencing short‑term price action.
Market read
Earnings surprise and crypto asset appreciation drive a sharp stock rally, offering a timely trading opportunity.
What to watch
Rising R&D costs and limited cash runway may limit long‑term sustainability.
Background
Cypherpunk Technologies is a privacy‑focused firm holding a large Zcash treasury and developing oncology drugs through Leap Therapeutics.
Ticker impact
Q2 profit of $39.4M driven by a $46M unrealized gain on ZEC holdings and FDA fast‑track designation for sirexatamab.
Further upside expected if ZEC price holds and trial progresses.
Strong earnings surprise combined with sizable crypto asset appreciation creates immediate buying pressure.
Market effects
Highlights growing link between crypto assets and biotech financing.
May boost interest in US micro‑caps with crypto treasuries.
Shows Zcash price movements can affect equity markets.
Counterpoint
Crypto volatility could reverse equity gains if ZEC price falls sharply.
Key entities
- companyCypherpunk Technologies Inc.
Issuer reporting Q2 results and ZEC treasury gains.
- subsidiaryLeap Therapeutics
Develops sirexatamab, now FDA fast‑track.



